Zimvie Inc. ( (ZIMV) ) has released its Q2 earnings. Here is a breakdown of the information Zimvie Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ZimVie Inc. is a global leader in the life sciences sector, specializing in dental implant solutions. The company is known for its comprehensive portfolio of products designed to support dental tooth replacement and restoration procedures, with a commitment to advancing clinical science and technology.
In its second-quarter 2025 earnings report, ZimVie Inc. announced a definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash. The company reported net sales of $116.7 million from continuing operations, with a net loss of $3.8 million, reflecting a net loss margin of 3.3%. Adjusted EBITDA from continuing operations stood at $17.5 million, with an adjusted EBITDA margin of 15.0%.
Key financial highlights from the quarter include a slight decrease in net sales by 0.1% compared to the previous year, with a constant currency decline of 2.1%. The net loss improved significantly by $5.7 million compared to the same period in 2024. Adjusted net income rose by $3.6 million to $7.2 million, while the adjusted diluted EPS was reported at $0.26.
ZimVie’s pending acquisition by ARCHIMED is expected to close by the end of 2025, subject to customary closing conditions and regulatory approvals. Upon completion, ZimVie will transition to a privately held entity, ceasing its public trading on the NASDAQ. The company has withdrawn its fiscal 2025 guidance due to the acquisition process.
Looking forward, ZimVie remains focused on executing its strategic initiatives and delivering value to its stakeholders, while navigating the transition to becoming a privately held company under ARCHIMED’s ownership.